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Abstract
Background: This paper addresses issues of brain tumor, glioma, classification from four modalities of Magnetic
Resonance Image (MRI) scans (i.e., T1 weighted MRI, T1 weighted MRI with contrast-enhanced, T2 weighted MRI and
FLAIR). Currently, many available glioma datasets often contain some unlabeled brain scans, and many datasets are
moderate in size.
Methods: We propose to exploit deep semi-supervised learning to make full use of the unlabeled data. Deep CNN
features were incorporated into a new graph-based semi-supervised learning framework for learning the labels of the
unlabeled data, where a new 3D-2D consistent constraint is added to make consistent classifications for the 2D slices
from the same 3D brain scan. A deep-learning classifier is then trained to classify different glioma types using both
labeled and unlabeled data with estimated labels. To alleviate the overfitting caused by moderate-size datasets,
synthetic MRIs generated by Generative Adversarial Networks (GANs) are added in the training of CNNs.
Results: The proposed scheme has been tested on two glioma datasets, TCGA dataset for IDH-mutation prediction
(molecular-based glioma subtype classification) and MICCAI dataset for glioma grading. Our results have shown good
performance (with test accuracies 86.53% on TCGA dataset and 90.70% on MICCAI dataset).
Conclusions: The proposed scheme is effective for glioma IDH-mutation prediction and glioma grading, and its
performance is comparable to the state-of-the-art.
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Background
Gliomas are the most common brain tumors [1–3], and
theymake up 80% of all malignant brain tumors [4]. Symp-
toms depend upon their locations within the brain, and
typically also vary with glioma grade and subtype. Accord-
ing to theWorldHealthOrganization (WHO), gliomas are
graded into four classes (grades I-IV) depending on their
aggressiveness. The diffuse gliomas with WHO grade
II are conventionally referred to as low-grade gliomas
(LGG), while high-grade gliomas (HGG) consist of those
with WHO grade III and IV. Recently molecular mark-
ers have revolutionized the classification. Glioma subtype
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isocitrate dehydrogenase (IDH) mutations are observed
in 12% of glioblastomas [5], and 70% to 80% of LGG
[6]. Patients with IDH mutated gliomas survive longer
than those with IDH wild-type gliomas [7–9]. Therefore,
IDH mutation information plays an important role in
the prognosis, diagnosis and guidance for clinical deci-
sions. To identify glioma subtype IDH mutation, tissue
diagnosis from an invasive procedure (e.g. biopsy or resec-
tion) is usually required, which might be risky to patients.
Seeking effective classification methods from Magnetic
Resonance Images (MRIs) may provide a non-invasive
option for the identification of IDH mutation subtype.
However, it is challenging as the IDH mutation informa-
tion is at the molecular level. Even medical experts cannot
easily observe such information from MRIs. Recently, a
lot of successful machine learning methods have been
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proposed for predicting the glioma types such as the
grade and the IDHmutation information fromMRIs non-
invasively, though many challenges remain that limit the
performance.
Related studies
Hand-crafted features (i.e. features designed by human
experts) for machine learning techniques have been
explored to characterize gliomas. Kang et al. [10] pro-
posed to grade glioma by the histogram analysis of appar-
ent diffusion coefficient maps. Carrillo et al. [11] pro-
posed to predict the status of IDH mutation on gliomas
by employing MRI features such as tumor size, frontal
lobe localization, presence of cysts and satellite lesions.
Another set of MRI features such as the pattern of growth,
tumor margins, signal density and contrast enhancement
were used by Qi et al. [12] on the same task of predict-
ing IDH mutation. Yu et al. [13] explored features such
as tumor location, intensity, shape, texture, and wavelet
features on the classification of grade II gliomas. Zhang
et al. [14] included Visually Accessible Rembrandt Images
(VASARI) features for predicting IDH and TP53 muta-
tions with SVM models. Shofty et al. [15] also extracted
tumor size, location and texture features but tested 17
machine learning classifiers on 1p/19q codeletion status
prediction for LGG. Zhou et al. [16] extracted histogram,
shape and texture features from preoperative MRIs, and
the age information is then integrated for training a ran-
dom forest classifier for the prediction of IDH mutation
status and 1p/19q codeletion. Although promising results
have been shown in these methods, choosing which fea-
ture to use is still empirical and dataset-dependent.
Deep learning offers another way for glioma character-
ization by automatically learning features. Several deep
learning-based glioma classification methods have been
proposed in the past few years. Li et al. [17] extracted
features from the last convolutional layer of a 6-layer
CNN segmentation network. These features were fur-
ther encoded by fisher vectors followed by feature selec-
tion and IDH mutation prediction using SVM classifiers.
Chang et al. [18] proposed to apply residual CNNs to
the prediction of IDH mutation using multi-institutional
MRI data from four different modalities: T1 weighted, T1
weighted with contrast enhanced, T2 weighted and FLAIR
(abbreviated as T1, T1ce, T2 and FLAIR in the text below).
Different strategies of fusing multi-view and multimodal
images were tested as well. Liang et al. [19] proposed to
use 3D MRI scans with more advanced DenseNets for
IDH mutation prediction. Their method was also applied
to the task of glioma grading with good performance.
Although existing methods for glioma classification
are promising, further improvement should be sought.
Gliomas are relatively rare, and most datasets are mod-
est in size. Since molecular markers are relatively newly
implemented in routine diagnostics, many images do not
have labels. The most direct way to tackle this is to only
use the labeled data for training, which is not a good strat-
egy as all the unlabeled data is wasted, given that the
glioma dataset is usually not sufficiently large and thus
very precious. Motivated by the medical needs, we aim
to make the best use of all the images including the unla-
beled ones to improve the classification performance. We
propose a novel deep semi-supervised learning method
for glioma classification. That is, the labels of the unla-
beled data are estimated by semi-supervised learning,
so that these images (with the estimated labels) can be
used together with the labeled data for training a classi-
fier. Conventional graph-based semi-supervised learning
framework treats all the labeled data equally, without con-
sidering the relations between the data. For the 2D MRIs
extracted from the same 3D scan of a patient, they should
have the same label. To address this issue, we add the 3D-
2D consistent constraint to both the graph construction
and the cost function to conduct label propagation. In this
way, semi-supervised learning tends to make consistent
predictions on the images from the same 3D scan. Since
most current glioma datasets are moderate in size, Gener-
ative Adversarial Networks (GANs) are also employed to
augment more synthetic MRIs to alleviate the overfitting
problem in CNNs. The main contributions of the paper
include:
• Propose to use deep semi-supervised learning for
estimating the labels of the unlabeled data, in order to
improve the performance of glioma classification by
exploring both the labeled and unlabeled data.
• Propose a 3D-2D consistent graph-based method for
semi-supervised learning, by adding constraints to
both the graph construction and the cost function of
label propagation, so that the consistent predictions
on the images from the same 3D scan can be made.
• Analyze and evaluate the performance of the
proposed method by extensive empirical tests on two
glioma dataset, including comparisons with some
state-of-the-art methods.
Methods
Overview of the proposed scheme
The main idea behind the proposed scheme is to improve
the performance of glioma classification by using the
unlabeled data in the training dataset, whose labels are
estimated by a novel graph-based deep semi-supervised
learning method. The novelties include: (a) Training
dataset employs both the labeled dataset as well as the
unlabeled dataset with estimated labels obtained from the
proposed semi-supervised method. By adding unlabeled
data and their corresponding estimated labels to the CNN
training, better performance is expected as more training
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data can mitigate the overfitting of deep learning. It offers
more robustness and improved generalization to the CNN
classifier. (b) Labels of the unlabeled data are estimated
by a graph-based semi-supervised learning method. The
3D-2D consistent constraint is introduced to improve the
convolutional graph-based label propagation framework,
based on the intuition that 2D MRIs from the same 3D
scan should have the same label of glioma. Such con-
straint is added to both the way of graph construction and
the cost function of label propagation for semi-supervised
learning.
The pipeline of the proposed scheme is shown in Fig. 1.
It consists of three modules, semi-supervised learning,
data augmentation and deep learning, and 3D volume-
based classification. Multi-stream 2D CNN is first trained
using only the labeled data in the training dataset. It is
then used to extract features from both the labeled and
unlabeled data in the training dataset. Graph-based semi-
supervised learning is used to learn the estimated labels
of the unlabeled data. Training data from both labeled
and unlabeled sets are fed into GANs to generate syn-
thetic MRIs for data augmentation. The labeled training
dataset, unlabeled training dataset with estimated labels
as well as the GAN-augmented data are used as input to
multi-stream 2D CNN for learning the characteristics of
gliomas. After that in the testing phase, MRI slices from
the testing dataset are tested using the trained CNN, fol-
lowed by post-processing to output the glioma type for
each 3D brain scan. The main contributions of this paper
include the graph-based semi-supervised learning and the
design of the whole scheme using unlabeled training data
for glioma type classification. In the following, a detailed
description of the graph-based semi-supervised learning
will be given.
Graph-Based semi-supervised learning
To estimate the labels for the unlabeled data, a new graph-
based semi-supervised learning method is proposed for
glioma type classification. This subsection describes the
graph-based semi-supervised learning method in the fol-
lowing three parts: problem formulation, graph construc-
tion and graph-based label propagation.
Problem formulation
Let X = {L, U} be the set of all the images. The images
xi ∈ L, i = 1, · · · , l, are labeled as y1, · · · , yl where
yi ∈ {1, · · · , c}, and c is the total number of classes. The
remaining images xi ∈ U , i = l + 1, · · · , n, are unlabeled.
Before semi-supervised learning, original images are usu-
ally mapped to a feature space Z = {z1, · · · , zn} where
zi = fθ (xi) and fθ (·) is the feature extraction function. In
this case, we use initially trained multi-stream 2D CNN
[20] for feature extraction (as shown in the deep feature
extraction block in Fig. 1). The aim of the semi-supervised
learning is to predict the labels ŷl+1, · · · , ŷn of the unla-
beled images in U using the feature set Z from all images
and the labels y1, · · · , yl from the labeled images in L.
Graph construction
To conduct graph-based semi-supervised learning, a
graph G = (V , E) is defined where vertices V denotes the
set of images and E is a set of graph edges. To form the
edges in E , a k nearest neighbour strategy is adopted by
connecting each image to its k nearest neighbours in the
feature space Z using the Euclidean distance. Observing
that images (corresponding to 2D slices of MRIs) belong-
ing to the same 3D scan should have the same label of
glioma type, these images are connected to each other in
the graph. Noting that some images from the same 3D
scan are not neighbours in the feature space due to varia-
tions and differences in angles. Such an edge construction
approachmakes it easier for the label information to prop-
agate among these images, so that they have a high prob-
ability to obtain the same (3D-2D consistent) label after
the graph-based semi-supervised learning. The affinity
matrix A ∈ Rn×n is calculated component-wise using the
Gaussian similarity in the feature space by
Fig. 1 The proposed deep semi-supervised learning scheme for glioma classification, whereL,U and T denote the labeled training dataset,
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if i = j and xi, xj are connected in the graph, where σ
is the standard deviation of the Gaussian function. The
affinity matrix is then converted to a symmetric version
W = (A + AT) /2 representing the pairwise similarity
between zi and zj. The degree matrix is defined as D =
diag(W1n) whose diagonal value Dii is the sum of the ith
row/column vector inW, and 1n is a n-dimensional vector
with all-one values.
Graph-Based label propagation
To estimate the labels of the unlabeled images, a new
graph-based label propagation method is proposed for
semi-supervised learning. The idea is to propagate the
label information from labeled images to unlabeled ones
through a graph, with an added 3D-2D consistent con-
straint to further improve its performance. The cost func-







‖2 + μ‖S − Y‖2F
+ λ‖S − BS‖2F ,
(2)
where S is the estimated labels for all images after label
propagation, si ∈ R1×c is the one-hot vector from the i-th
row of S denoting the label for the i-th image, μ > 0 and
λ > 0 are the balancing weights. The one-hot label matrix
Yn×c is defined as
Yi,j =
{
1, if xi ∈ L and yi = j,
0, otherwise. (3)
The first term in (2) is the smoothness constraint where
images that are close to each other in the feature space
have similar labels. The second term is the fitting con-
straint to force the labeled images to remain their labels.
These two terms are adopted from [21] as the framework
for label propagation. The third term is to enforce the
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We assume that each patient’s 3D scan contains ns 2D
MR image slices, and the first set of ns images x1, x2, ..., xns
are from the first patient, the second set of ns images
xns+1, xns+2, ..., x2×ns are from the second patient, and so
on. The 3D scan-consistent restraint term ‖S−BS‖2F may
be further expanded as
‖S − BS‖2F =
n∑
i=1
‖si − smi‖22, (5)
where smi = 1ns
∑i/ns×ns+ns
j=i/ns×ns+1 sj, and smi is the mean
prediction of the 2D image slices xi for the same 3D scan.
The constraint term in (5) is a variance penalty forcing the
images from the same patient to have the same label. Here
we choose the variance of the predictions as the penalty,
other metrics that can reflect their consistencies such as
entropy may also be adopted.
To minimize the cost function, applying partial deriva-
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The estimated matrix of labels S is obtained as
S = μ
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where I is the identical matrix with dimension n×n. The
symmetric normalized Laplacian matrix I − D− 12WD− 12
is semi-positive definite, and (I − B)T (I − B) is semi-
positive definite. With μ > 0 and λ > 0, (1 + μ)I −
D− 12WD− 12 +λ(I−B)T (I−B) is positive definite and thus
invertible. It is worth noting that if the number of images
n is large, the closed-form solution in (6) is not practical.
One can resort to the conjugate gradient method [22] or
the iterative method [21] for an approximate solution.
The estimation of the label for the unlabeled image xi is
obtained from examining the label vector si such that
ŷi = argmax
j
si,j, i ∈ {l + 1, · · · , n} , (7)
where si,j is the jth element of vector si.
The algorithm of the graph-based semi-supervised
learning for glioma classification is summarized in
Algorithm 1 below.
Implementation issues
Multi-Stream 2D convolutional neural network (CNN) for
supervised learning
We adopt themulti-stream 2DCNN in [20] as the baseline
method for the feature learning/extraction and classifica-
tion of 2D MR image slices, followed by post-processing
for 3D tumor type estimation, where the block diagram is
depicted in Fig. 2. This baseline method contains four sep-
arate streams for learning glioma features in eachmodality
of MR image slices followed by the fusion of four modality
features. The 2D CNN of each stream has seven convo-
lutional layers with filter size 3×3 in each layer. Feature
map of each stream is extracted from the last convolu-
tional layer, and then the four streams of features are
fed to the feature fusion and enhancement layers. We
apply a weighted sum on these features through the atten-
tion weights, which are learned adaptively according to
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Algorithm 1 Graph-Based Semi-Supervised Learning
Input: feature set Z from all images in {L,U}, labels {yi} from labeled images xi in L, i ∈ {1, · · · , l}.
1. Construct a graph by connecting each image to its k nearest neighbors and those coming from the same 3D scan.
2. Calculate the symmetric affinity matrixW and the degree matrix D from (1).
3. Calculate the label matrix Y using (3).
4. Set the matrix B using (4);
5. Calculate the estimated label set S using (6).
6. Obtain ŷj for the unlabeled images using (7);
Output: the estimated labels {ŷj} for the images xj in U , j ∈ {l + 1, · · · , n}.
their modality-specific characteristics. Feature enhance-
ment layer is employed to map the fused features to a
high-dimensional feature space, leading to the feature rep-
resentation with complementary information from differ-
ent modalities. After that, the enhanced feature map is fed
to the classifier consisting of 3 fully-connected (FC) layers
for the slice-based classification. Post-processing is finally
conducted using majority voting on slice-based classifica-
tion results, and it results in the brain tumor classification
based on 3D scans.
Pairwise GAN for augmenting brainMRI slices
The pairwise GAN [20] is used to augment synthetic
MRIs across different modalities for fake patients. It offers
more robustness as GAN-augmented MRIs covers more
tumor statistics according to their distributions. In pair-
wise GANs, two streams of GANs (generatorsGm ,Gn and
discriminatorsDm,Dn) are interconnected. The loss func-
tion consists of adversarial loss Lm, Ln and pixel-level loss
L1(Gm,Gn), where tumor masks are used in L1(Gm,Gn)
to enhance the pixels in the tumor area for generating
more realistic tumors. Formore details please refer to [20].
The GAN-augmented images are used initially for pre-
trainingmulti-stream 2DCNN for glioma feature learning
and classification, and then the real MRIs are used for
refined-training.
Estimating the labels of GAN-augmentedMRI slices
In the proposed scheme, semi-supervised learning is used
for estimating the labels of the unlabeled MRI slices in
the training dataset, to include more data in the training
Fig. 2 The baseline method of multi-stream 2D CNN for supervised
learning and classification of gliomas in [20]
dataset. Meanwhile, to check whether GAN-augmented
MRI slices have the right labels, these slices are also
treated as the unlabeled data in the framework of semi-
supervised learning. The estimated labels of the GAN-
augmented MRI slices by semi-supervised learning are
further compared with their original labels to remove out-
liers. Only GAN-augmented slices whose original labels
are the same as the estimated labels by semi-supervised
learning are added to the training dataset.
Results
Setup, datasets andmetrics
Setup: KERAS library [23] with TensorFlow [24] back-
end was used for our experiments. All experiments were
done on a workstation with Intel-i7 3.40GHz CPU, 48G
RAM and an NVIDIA Titan Xp 12GB GPU. Hyperpa-
rameter settings were as follows: for TCGA dataset, pre-
training was applied to GAN augmented images using
100 epochs with the learning rate 1e-4 for epochs∈[1,30],
1e-5 for epochs∈[31,60], and 1e-6 for epochs∈[61,100].
Refined training was then applied to the original images
using 50 epochs with the learning rate 1e-5. For MIC-
CAI dataset, pretraining was applied to GAN augmented
images using 70 epochs with the learning rate 1e-4 for
epochs∈[1,50], 1e-5 for epochs∈[51,70]. Refined training
was then applied to the real images by using 70 epochs
with the learning rate 1e-4 for epochs∈[1,40], and 1e-6 for
epochs∈[41,70]. Optimizer was Adagrad. Batch size was
9. L2 regularization term was applied with parameter 1e-
4. Dropout rate was set to 0.5 in the FC layers. Simple
augmentation strategies such as flipping (horizontal) and
shifting (max 10% of image width and height) were also
used. They were realized by Keras function ImageData-
Generator, and only performed on the training dataset in
real time to minimize the memory usage.
Datasets: Two datasets were used in our experiments.
TCGA dataset contains 3D brain scans (i.e., 3D volume
images) fromTCGA-GBM [25] and TCGA-LGG [26] with
IDH genotype labels. MICCAI dataset contains 3D brain
scans of low-grade glioma (LGG) and high-grade glioma
(HGG), downloaded from MICCAI BraTS 2017 competi-
tion [27, 28]. Both datasets contain four types of 3D brain
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Table 1 Information of the two datasets based on 3D brain scan, where 9 image slices per 3D scan were used in all our experiments
Dataset Tumor #Patients #3D scans #3D scans #3D scans #3D scans
type (T1/T1ce/ for training for validation for testing
T2/FLAIR) (origial/GAN (original) (original)
augmented)
TCGA IDH mutation 55 55 33/99 6 16
IDH wild-type 112 112 66/198 13 33
MICCAI HGG 210 210 126/126 21 63
LGG 75 75 45/45 7 23
Further, the training/validation/testing sets were patient-wise partitioned according to 60%,10%,30% approximately, and 2/3 of the original scans in the training datasets
were labeled, and the remaining 1/3 were set as unlabeled
MRI scans (T1, T1ce, T2, FLAIR) and tumor segmenta-
tion results. Although TCGA and MICCAI datasets have
some overlap on IDH genotype, the class labels for MIC-
CAI dataset used in our study are only related to low and
high grades of gliomas (LGG/HGG), not genotypes.
For TCGA dataset the aim is to classify/predict the tumor
subtypes in the molecular levels by using multimodal
MRIs. For MICCAI dataset the aim is to classify the
glioma into low and high grades. Detailed information of
two datasets is given in Table 1.
Example images of four modalities in two classes are
shown in Fig. 3. Since the volume of tumor is usually
small/medium in size, 9 slices that contain gliomas were
extracted from each individual scan. This was done for
both classes. For focusing feature learning on the tumor
areas instead of the whole brain, tumor masks were
applied to enhance the tumor feature learning by multi-
plying the background pixels by a factor of 1/3. For all
our experiments, dataset was partitioned into 3 subsets:
training (60%), validation (10%) and testing (30%). All 2D
image slices in these 3 subsets were partitioned according
to patients, i.e., images from the same patient were kept
together in either training subset or the testing subset, as
such partition was clinically important. 2/3 of the training
dataset (for both original and GAN augmented data) was
labeled and the other 1/3 was set as unlabeled.
Metrics for performance evaluation: Cross-entropy
loss was used as the loss function for evaluating the
Fig. 3 Examples of 2D MRI slices from IDH mutation/wild-type gliomas and LGG/HGG in four modalities
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Fig. 4 Training and validation curves (accuracy vs. epoch) on the two datasets. Left: TCGA dataset, where epochs 1-100 were from the pre-training
and epochs 101-150 were from the refined training; Right: MICCAI dataset, where epochs 1-70 were from the pre-training and epochs 71-140 were
from the refined training
performance of CNN training. To evaluate the perfor-
mance of the glioma classification, we used the accuracy,
sensitivity and specificity in (8) as the criteria on the
results obtained from the test set averaged over 5 runs,
Accuracy = TP+TNTP+FP+TN+FN ,
Sensitivity = TPTP+FN , Specificity = TNFP+TN ,
(8)
where one has the following definitions by selecting IDH
mutation/LGG as the target class:
True positive (TP): IDH mutation glioma/LGG was cor-
rectly classified as IDH mutation/LGG.
False positive (FP): IDHwild-type glioma/HGGwas incor-
rectly classified as IDH mutation/LGG.
True negative (TN): IDH wild-type glioma/HGG was cor-
rectly classified as IDH wild-type/HGG.
False negative (FN): IDH mutation glioma/LGG was
incorrectly classified as IDH wild-type/HGG.
Performance of the proposedmethod
To test the effectiveness of the proposed deep semi-
supervised learning for classifying gliomas, experiments
were conducted with 5 runs on two datasets, where the
partitions of training, validation and testing subsets were
done randomly in each run. Figure 4 shows the train-
ing and validation curves in the training process for two
datasets from the first run.
Observing Fig. 4, training has converged for both
datasets, with high validation accuracies showing good
generalization ability for the unseen data. The gap
between the training and validation performance also
indicates small overfitting probably due to the moderate
size of training dataset.
Table 2 shows the test results and performance obtained
from the proposed scheme on TCGA and MICAII
datasets. Table 2 (a) shows the performance of the 5 runs
on testing sets with the mean accuracy as well as the stan-
dard deviation, (b) and (c) show the confusion matrices
from test results on two datasets.
Observing Table 2(a), the proposed method was shown
to be effective according to the test accuracies on two
datasets. For TCGA dataset, a relatively high average
accuracy of 86.53% was achieved, with average sensitiv-
ity 73.75% and specificity 92.73%. For MICCAI dataset,
average test accuracy was 90.70% with sensitivity 84.35%
and specificity 93.01%. Test results from both datasets
were reasonably well. Since the tests on TCGA dataset
were aimed at predicting of IDH genotypes, which was
a more challenging task than that of tumor grading on
MICCAI dataset, the slightly lower test performance on
TCGA dataset than that on MICCAI dataset (86.53% vs.
90.70%) was expected. Further, observing the confusion
matrix in Table 2(b), relatively higher accuracy was on
IDH wild-type class but lower accuracy on IDH mutation
class, indicating more false alarm on IDH wild-type class.
From Table 2(c) one can see the accuracy on HGG was
higher than that of LGG. The unbalanced test accuracies
on the two classes, and the difference between specificity
Table 2 Test results and performance obtained from the
proposed scheme on TCGA and MICAII datasets
(a)Average accuracy, sensitivity and specificity on the test sets, where
the standard deviation is included in (·) after each performance value.
Dataset Accuracy (|σ |) Sensitivity (|σ |) Specificity (|σ |)
TCGA 86.53(4.24) 73.75(8.15) 92.73(3.45)
MICCAI 90.70(1.42) 84.35(6.59) 93.01(1.42)
(b) The confusion matrix from test results on the TCGA dataset.
True\ Classified IDH mutation IDH wild-type
IDH mutation 73.75 26.25
IDH wild-type 7.27 92.73




All results were obtained by averaging over 5 runs, and |σ | is the standard
deviation, all values in the tables (a) (b) and (c) are in percentage %
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Fig. 5 Performance on the TCGA dataset, where the results were obtained from the test set averaged over 5 runs. Left: performance where GAN
augmented data was added in the training set; Right: performance where no GAN augmented data was used in the training set. Red: from the
proposed semi-supervised scheme; Black: from baseline-1 method; Blue: from baseline-2 method
and sensitivity from two datasets were likely caused by
the unbalanced number of brain MRIs in the two classes
(both IDH mutation/wild-type and HGG/LGG) as shown
in Table 1.
Comparison with baseline methods
We define three different methods for evaluating the
performance of the proposed semi-supervised learning
scheme for glioma classification:
Baseline-1 method: the training dataset only consisted of
the original labeled 2D image slices L plus GAN aug-
mented images based onL, where pretraining was applied
on GAN-augmented image set.
Proposed scheme: the training dataset consisted of the
original labeled 2D image slices L and unlabeled ones
U whose labels were estimated from graph-based semi-
supervised learning. Pretraining was applied on the GAN-
augmented images where a small number of outlier
images from GANs were removed.
Baseline-2 method: the training dataset consisted of the
original labeled 2D image slices L and U in which the
ground-truth labels were used. Pretraining was applied on
the GAN-augmented image slices where a small number
of outlier images of GANs were removed.
Results on two different settings, with and without
adding GAN-augmented data for the pre-training, are
shown in Fig. 5, where the average results over 5 runs as
well as the standard deviation |σ | for the overall accuracy,
sensitivity, and specificity are included.
Observing Fig. 5, the proposed scheme on two cases
(with and without GAN) achieved better performance
than the baseline-1 method according to the accuracy,
while slightly lower performance than the baseline-2
method. This result indicates that the proposed semi-
supervised learning scheme is effective in estimating the
labels for the unlabeled training data U , which has con-
tributed to the performance improvement as compared
with the baseline-1 method without using unlabeled data
in U . The small gap between the proposed method and
baseline-2 method also suggests that the estimated labels
by semi-supervised learning were close to those of the
real labels, thus leading to the similar performance on
the testing sets. One can see from the right image in
Fig. 5 that sensitivity has dropped compared to the two
baseline methods, with increased specificity. This was
probably due to the similar reason (as in Table 2) of using
imbalanced number of training data between the two
classes.
A similar comparison between the proposed scheme
and the two baseline methods was also done by using the
test results averaged over 5 runs on the MICCAI dataset,
as shown in Fig. 6.
Fig. 6 Performance on the MICCAI dataset, where the results were obtained from the test set averaged over 5 runs. Left: performance where GAN
augmented data was added in the training set; Right: performance where no GAN augmented data was used in the training set. Red: from the
proposed semi-supervised scheme; Black: from baseline-1 method; Blue: from baseline-2 method
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Observing Fig. 6, the proposed scheme has achieved
improved accuracy compared to baseline-1 method but
lower accuracy than baseline-2 method for both cases.
The sensitivity rate has dropped in the proposed method
with additional gain in the specificity rate. One can
observe that both in Figs. 5 and 6, there was a relatively
big difference between the sensitivity and specificity val-
ues. This was probably due to the imbalanced training
data in the two classes (for both TCGA and MICCAI
dataset). Further, the semi-supervised learning has gen-
erated increased performance for the class with more
training data, at the cost of decreased performance for the
class with less training data.
Impact of adding GAN-augmented images in the training
To evaluate the impact of adding GAN-augmented MR
image slices in the training dataset, a comparison was
made for the methods with and without including GAN-
augmented images in the training datasets of TCGA and
MICCAI.Mean accuracy and standard deviation averaged
over 5 runs are shown in Fig. 7 and Table 3.
Observing Fig. 7, adding GAN-augmented data in the
pre-training before refined training on real brainMRI data
has improved test accuracies on both datasets. Observing
the test results on TCGA dataset in Table 3, the proposed
method by adding GAN-augmented training data has led
to improved average accuracy and an improved specificity
rate. From the test results of MICCAI dataset in Table 3,
the proposed method by adding GAN-augmented data
has resulted in the improved sensitivity by 6.09% and a
slight drop in specificity. Overall, addingGAN-augmented
data in the training dataset has shown to be effective for
improving the test performance of glioma classification on
these two datasets.
Fig. 7 Test accuracy from the proposed scheme on TCGA and MICCAI
datasets, with/without adding GAN augmented images in the
training set. Blue: without using GAN augmented images; Red: with
GAN augmented images
Table 3 Test performance from the proposed scheme on TCGA
and MICCAI datasets with and without adding GAN-augmented
images in the training
Dataset GAN Accuracy(|σ |) Sensitivity(|σ |) Specificity(|σ |)
TCGA Without 85.30(4.43) 73.75(9.27) 90.91(5.25)
With 86.53(4.24) 73.75(8.15) 92.73(3.45)
MICCAI Without 89.53(1.42) 78.26(4.35) 93.65(2.75)
With 90.70(1.42) 84.35(6.59) 93.01(1.42)
Results are shown in mean value (standard deviations |σ |) over 5 runs, all values are
in percentage %. The best results in accuracy/sensitivity/specificity are marked in
boldface
Comparison to the state-of-the-art methods
The performance of several existing methods on
two datasets for classifying glioma types with IDH
mutation/wild-type and glioma grades are shown in
Tables 4 and 5. All the other methods in Tables 4 and 5,
used for comparison with the proposed method, have
applied supervised training by using fully annotated
datasets. It is worth noting that results from [13, 14, 17,
18] in Table 4, and the results from [29] in Table 5 can
only be used as an indication since they were applied in
different datasets. [30] used a very different approach as
our proposed scheme here, which applied a 3D multiscale
CNN network directly on 3D T1ce MR images, with fully
annotated training dataset.
Observing Tables 4 and 5, it is shown that the proposed
method is better than those in [19, 30] in terms of test
accuracy. It is also indicated that the proposedmethod has
reached high performance as comparing with the meth-
ods in [13, 14, 17, 18], noting the results were obtained
from different datasets with different number of patients.
These comparisons have also indicated that the proposed
deep semi-supervised learning is effective in estimating
the labels of the unlabeled data, with the performance
reaching the existing state-of-the-art methods.
Table 4 Comparison of IDH mutation/wide type classification
from the proposed scheme and some existing methods
Method # Patients with IDH Test
mutation/wild-type Accuracy (%)
Liang [19] 55/112 84.60
Proposed 55/112 86.53
Yu [13] 76/34 80.00
Zhang [14] 70/33 80.00
Li [17] 89/30 86.55
Chang [18] 233/263 85.70
Noting that [13, 14, 17, 18] were applied to different datasets, hence they were only
used here as the indication/reference to the state-of-the-art in IDH
mutation/wild-type classification. The performance of the proposed method is in
boldface
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Table 5 Comparison of low/high grade glioma classification
from the proposed scheme and some existing methods
Method # Patients with Test
HGG/LGG Accuracy (%)
Pan [29] 188/25 73.33
Ge [30] 210/75 89.47
Proposed 210/75 90.70
The performance of the proposed method is in boldface
Discussion
From our experimental results, some insights can be
gained from the proposed scheme:
• High overall performance was achieved on two
datasets for two different glioma classification tasks:
molecular-based glioma subtype classification (to
classify IDH mutation/wild-type), and glioma grading
(to classify high-grade/low-grade gliomas).
• Semi-supervised learning scheme is effective for
estimating the labels for the unlabeled dataset. With
the unlabeled data and the estimated labels obtained
from semi-supervised learning, the proposed scheme
achieved improved performance compared to the
baseline without using any unlabeled data. This
indicates that the proposed semi-supervised glioma
classification scheme is useful in real scenarios when
part of the labels in the dataset is missing and the
labeled dataset is small.
• Adding GAN-augmented data in the training dataset
for pretraining has improved the classification
performance on the testing set. It suggests that GANs
are useful in augmenting synthetic MRIs, and
pretraining with GAN augmented data followed by
refined training with real MRI data, has improved the
generalization performance on the unseen testing
dataset for glioma classification.
• Large imbalanced training data between classes is
undesirable, as this may result in relatively large
differences of performance between individual
classes.
• Comparison of performance with several state-of-
the-art methods has indicated that the proposed
semi-supervised approach has reached comparable
performance to those of fully supervised ones.
Limitation: The imbalance of training data (including
GAN generated training data) in two different classes has
caused one class with relatively lower performance, con-
sequently, it has affected the average test performance.
Possible solutions could be to extract more 2D MRI slices
for the class with smaller number of patients, and to
explore other types of GANs allowing augmenting more
MRI slices covering a wider range of tumor statistics.
Conclusion
The proposed scheme has been tested on two glioma
classification datasets, and results have shown the effec-
tiveness of the proposed scheme with high average test
accuracies (86.53% for twomolecular-based subtypes IDH
mutation/wild-type, and 90.7% for high-grade/low-grade
gliomas). Using graph-based semi-supervised learning for
estimating the labels of the unlabeled data in the training
dataset has resulted in the increased performance on the
testing dataset. This indicates that the proposed scheme is
useful in the real scenarios when some labels of the data in
a dataset are missing. Adding GAN-augmented data in the
training dataset is useful for increasing the generalization
performance on the testing dataset. Finally, comparisons
with several different methods, although based on dif-
ferent datasets, have shown that the proposed method
is comparable to the state-of-the-art. Limitation of the
method is also discussed. Future work will be on extend-
ing glioma subtypes to include both IDH genotype and
1p/19q codeletion status, and incorporating patient side
information (e.g. ages, survival years).
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